Measurable residual disease in multiple myeloma: ready for clinical practice?

The landscape of multiple myeloma (MM) has changed considerably in the past two decades regarding new treatments, insight into disease biology and innovation in the techniques available to assess measurable residual disease (MRD) as the most accurate method to evaluate treatment efficacy. The sensit...

Descripción completa

Detalles Bibliográficos
Autores principales: Burgos, Leire, Puig, Noemi, Cedena, Maria-Teresa, Mateos, María-Victoria, Lahuerta, Juan José, Paiva, Bruno, San-Miguel, Jesús F.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2020
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7310444/
https://www.ncbi.nlm.nih.gov/pubmed/32571377
http://dx.doi.org/10.1186/s13045-020-00911-4

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7310444/
https://www.ncbi.nlm.nih.gov/pubmed/32571377
http://dx.doi.org/10.1186/s13045-020-00911-4

Ejemplares similares